 Matthew Greenhawt
Concepts (516)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Food Hypersensitivity | 100 | 2024 | 254 | 29.170 |
Why?
| | Peanut Hypersensitivity | 66 | 2023 | 201 | 24.970 |
Why?
| | Anaphylaxis | 56 | 2023 | 148 | 21.090 |
Why?
| | Allergens | 74 | 2024 | 427 | 12.440 |
Why?
| | Desensitization, Immunologic | 36 | 2024 | 117 | 10.770 |
Why?
| | Arachis | 47 | 2023 | 149 | 10.680 |
Why?
| | Epinephrine | 29 | 2023 | 166 | 9.380 |
Why?
| | Hypersensitivity | 29 | 2023 | 272 | 9.010 |
Why?
| | Egg Hypersensitivity | 19 | 2023 | 45 | 6.710 |
Why?
| | Cost-Benefit Analysis | 25 | 2023 | 545 | 5.350 |
Why?
| | Drug Hypersensitivity | 11 | 2023 | 86 | 4.970 |
Why?
| | Pandemics | 21 | 2022 | 1333 | 4.150 |
Why?
| | Skin Tests | 26 | 2022 | 137 | 4.100 |
Why?
| | Asthma | 31 | 2023 | 2152 | 3.940 |
Why?
| | Eczema | 17 | 2023 | 83 | 3.890 |
Why?
| | Pneumonia, Viral | 10 | 2020 | 343 | 3.850 |
Why?
| | Coronavirus Infections | 10 | 2020 | 335 | 3.840 |
Why?
| | Allergy and Immunology | 14 | 2020 | 56 | 3.800 |
Why?
| | Eosinophilic Esophagitis | 14 | 2023 | 295 | 3.790 |
Why?
| | Caregivers | 16 | 2023 | 714 | 3.730 |
Why?
| | Humans | 287 | 2024 | 115908 | 3.510 |
Why?
| | Quality of Life | 32 | 2024 | 2392 | 3.130 |
Why?
| | Vaccines | 8 | 2023 | 376 | 3.120 |
Why?
| | Influenza Vaccines | 10 | 2018 | 498 | 2.740 |
Why?
| | Betacoronavirus | 7 | 2020 | 253 | 2.730 |
Why?
| | Child | 95 | 2024 | 18555 | 2.640 |
Why?
| | Practice Guidelines as Topic | 26 | 2024 | 1403 | 2.590 |
Why?
| | Dermatitis, Atopic | 13 | 2023 | 337 | 2.540 |
Why?
| | Nut Hypersensitivity | 5 | 2019 | 9 | 2.500 |
Why?
| | Food | 15 | 2024 | 160 | 2.490 |
Why?
| | Immunoglobulin E | 24 | 2023 | 363 | 2.420 |
Why?
| | Immunotherapy | 14 | 2023 | 480 | 2.420 |
Why?
| | Urticaria | 5 | 2022 | 51 | 2.410 |
Why?
| | Health Care Costs | 5 | 2022 | 386 | 2.260 |
Why?
| | Milk Hypersensitivity | 5 | 2023 | 22 | 2.260 |
Why?
| | Infant | 58 | 2023 | 8002 | 2.190 |
Why?
| | Enterocolitis | 6 | 2020 | 33 | 2.110 |
Why?
| | Hypersensitivity, Immediate | 4 | 2023 | 57 | 2.070 |
Why?
| | Vaccination | 13 | 2022 | 1205 | 1.990 |
Why?
| | Influenza, Human | 7 | 2018 | 549 | 1.970 |
Why?
| | Child, Preschool | 47 | 2023 | 9175 | 1.920 |
Why?
| | School Health Services | 4 | 2020 | 206 | 1.840 |
Why?
| | Infant Nutritional Physiological Phenomena | 7 | 2023 | 133 | 1.700 |
Why?
| | United States | 49 | 2023 | 12338 | 1.660 |
Why?
| | Omalizumab | 4 | 2020 | 46 | 1.590 |
Why?
| | Risk | 10 | 2020 | 830 | 1.520 |
Why?
| | Dietary Exposure | 3 | 2019 | 7 | 1.510 |
Why?
| | Rhinitis, Allergic | 5 | 2023 | 37 | 1.490 |
Why?
| | Injections, Intramuscular | 6 | 2023 | 118 | 1.420 |
Why?
| | Allergists | 7 | 2023 | 19 | 1.370 |
Why?
| | Decision Support Techniques | 4 | 2020 | 352 | 1.340 |
Why?
| | Milk | 7 | 2023 | 124 | 1.330 |
Why?
| | Bronchodilator Agents | 6 | 2023 | 251 | 1.330 |
Why?
| | Sympathomimetics | 2 | 2019 | 25 | 1.310 |
Why?
| | Anti-Asthmatic Agents | 5 | 2021 | 350 | 1.300 |
Why?
| | Surveys and Questionnaires | 21 | 2023 | 4670 | 1.300 |
Why?
| | Immune Tolerance | 7 | 2019 | 331 | 1.250 |
Why?
| | Primary Prevention | 7 | 2022 | 171 | 1.240 |
Why?
| | Population Groups | 3 | 2019 | 58 | 1.230 |
Why?
| | Cost of Illness | 3 | 2021 | 258 | 1.220 |
Why?
| | Patient-Centered Care | 5 | 2021 | 475 | 1.210 |
Why?
| | Health Literacy | 3 | 2020 | 166 | 1.200 |
Why?
| | Health Policy | 4 | 2020 | 332 | 1.170 |
Why?
| | Emergency Medical Services | 7 | 2021 | 591 | 1.160 |
Why?
| | Canada | 10 | 2022 | 337 | 1.110 |
Why?
| | Self Administration | 4 | 2020 | 124 | 1.110 |
Why?
| | Eggs | 5 | 2023 | 30 | 1.110 |
Why?
| | Delivery of Health Care | 5 | 2020 | 847 | 1.090 |
Why?
| | Drug-Related Side Effects and Adverse Reactions | 2 | 2020 | 242 | 1.090 |
Why?
| | Social Media | 5 | 2020 | 135 | 1.090 |
Why?
| | Female | 67 | 2023 | 60086 | 1.080 |
Why?
| | Schools | 6 | 2021 | 401 | 1.030 |
Why?
| | Patient Participation | 4 | 2024 | 362 | 1.020 |
Why?
| | Age Factors | 14 | 2020 | 2912 | 1.000 |
Why?
| | Communication | 3 | 2020 | 749 | 1.000 |
Why?
| | Evidence-Based Medicine | 7 | 2020 | 686 | 0.970 |
Why?
| | Checklist | 2 | 2023 | 84 | 0.960 |
Why?
| | Practice Patterns, Physicians' | 7 | 2023 | 1177 | 0.940 |
Why?
| | Adolescent | 33 | 2023 | 17955 | 0.930 |
Why?
| | Health Personnel | 3 | 2021 | 578 | 0.910 |
Why?
| | Personal Protective Equipment | 2 | 2020 | 50 | 0.890 |
Why?
| | Rhinitis | 3 | 2022 | 128 | 0.890 |
Why?
| | Biological Products | 2 | 2023 | 172 | 0.870 |
Why?
| | Male | 51 | 2023 | 56128 | 0.870 |
Why?
| | Probiotics | 2 | 2023 | 47 | 0.850 |
Why?
| | National Institute of Allergy and Infectious Diseases (U.S.) | 9 | 2019 | 28 | 0.850 |
Why?
| | Quality-Adjusted Life Years | 5 | 2021 | 103 | 0.840 |
Why?
| | Telemedicine | 5 | 2022 | 667 | 0.820 |
Why?
| | Gastritis | 1 | 2023 | 84 | 0.800 |
Why?
| | Clinical Decision-Making | 4 | 2020 | 275 | 0.800 |
Why?
| | Infant Formula | 2 | 2023 | 74 | 0.800 |
Why?
| | Milk Proteins | 3 | 2022 | 36 | 0.800 |
Why?
| | Enteritis | 1 | 2023 | 82 | 0.800 |
Why?
| | Rhinitis, Allergic, Seasonal | 2 | 2019 | 33 | 0.800 |
Why?
| | Sublingual Immunotherapy | 2 | 2022 | 7 | 0.790 |
Why?
| | Food Labeling | 4 | 2019 | 16 | 0.780 |
Why?
| | Penicillins | 2 | 2021 | 52 | 0.750 |
Why?
| | Nuts | 2 | 2019 | 12 | 0.750 |
Why?
| | Siblings | 2 | 2019 | 229 | 0.750 |
Why?
| | Anti-Bacterial Agents | 4 | 2023 | 1486 | 0.740 |
Why?
| | Eosinophilia | 1 | 2023 | 187 | 0.740 |
Why?
| | Infectious Disease Transmission, Patient-to-Professional | 1 | 2020 | 21 | 0.740 |
Why?
| | Influenza A Virus, H1N1 Subtype | 2 | 2013 | 139 | 0.730 |
Why?
| | Women's Health | 1 | 2022 | 271 | 0.710 |
Why?
| | Physicians | 4 | 2021 | 774 | 0.710 |
Why?
| | Administration, Oral | 10 | 2024 | 731 | 0.710 |
Why?
| | Adult | 34 | 2023 | 30820 | 0.710 |
Why?
| | Consensus | 6 | 2023 | 533 | 0.700 |
Why?
| | Dietary Proteins | 3 | 2020 | 126 | 0.690 |
Why?
| | Markov Chains | 5 | 2022 | 115 | 0.690 |
Why?
| | Diet | 8 | 2022 | 1075 | 0.690 |
Why?
| | Observation | 1 | 2019 | 50 | 0.690 |
Why?
| | Inservice Training | 1 | 2020 | 107 | 0.680 |
Why?
| | Patient Care | 1 | 2020 | 103 | 0.680 |
Why?
| | Anti-Allergic Agents | 1 | 2019 | 41 | 0.680 |
Why?
| | Risk Reduction Behavior | 3 | 2018 | 196 | 0.670 |
Why?
| | Health Knowledge, Attitudes, Practice | 5 | 2018 | 1193 | 0.670 |
Why?
| | Bites and Stings | 1 | 2019 | 30 | 0.670 |
Why?
| | Carmine | 2 | 2009 | 2 | 0.670 |
Why?
| | Job Satisfaction | 1 | 2021 | 170 | 0.670 |
Why?
| | Juglans | 1 | 2019 | 7 | 0.670 |
Why?
| | Infection Control | 1 | 2020 | 137 | 0.670 |
Why?
| | Aircraft | 1 | 2019 | 28 | 0.660 |
Why?
| | Biological Therapy | 1 | 2019 | 26 | 0.660 |
Why?
| | Evidence-Based Practice | 2 | 2020 | 190 | 0.650 |
Why?
| | Pathology, Molecular | 1 | 2019 | 26 | 0.640 |
Why?
| | Burnout, Professional | 2 | 2021 | 321 | 0.640 |
Why?
| | Protein Hydrolysates | 1 | 2018 | 7 | 0.630 |
Why?
| | Multiphasic Screening | 1 | 2018 | 3 | 0.630 |
Why?
| | Immunomodulation | 2 | 2019 | 86 | 0.630 |
Why?
| | United States Food and Drug Administration | 3 | 2020 | 173 | 0.630 |
Why?
| | Health Promotion | 3 | 2023 | 690 | 0.630 |
Why?
| | Polysorbates | 3 | 2023 | 35 | 0.620 |
Why?
| | Population | 1 | 2018 | 29 | 0.620 |
Why?
| | Ambulatory Care Facilities | 1 | 2020 | 210 | 0.620 |
Why?
| | Watchful Waiting | 1 | 2018 | 57 | 0.620 |
Why?
| | Students | 3 | 2017 | 503 | 0.620 |
Why?
| | Food, Genetically Modified | 1 | 2017 | 3 | 0.600 |
Why?
| | Orthomyxoviridae | 1 | 2018 | 35 | 0.600 |
Why?
| | Prejudice | 1 | 2018 | 55 | 0.600 |
Why?
| | Air Travel | 2 | 2018 | 2 | 0.600 |
Why?
| | Plants, Genetically Modified | 1 | 2017 | 18 | 0.600 |
Why?
| | Research Design | 4 | 2023 | 947 | 0.600 |
Why?
| | Plant Proteins | 1 | 2018 | 80 | 0.600 |
Why?
| | Environmental Exposure | 2 | 2018 | 381 | 0.590 |
Why?
| | Crops, Agricultural | 1 | 2017 | 31 | 0.590 |
Why?
| | Home Care Services | 1 | 2020 | 226 | 0.570 |
Why?
| | Antibodies, Monoclonal, Humanized | 3 | 2022 | 665 | 0.570 |
Why?
| | Public Health | 2 | 2020 | 439 | 0.550 |
Why?
| | Esophagus | 3 | 2019 | 224 | 0.550 |
Why?
| | Student Health Services | 2 | 2014 | 16 | 0.550 |
Why?
| | Eosinophils | 3 | 2020 | 283 | 0.550 |
Why?
| | Risk Assessment | 8 | 2023 | 3004 | 0.540 |
Why?
| | Advisory Committees | 7 | 2024 | 208 | 0.540 |
Why?
| | Influenza A virus | 2 | 2015 | 91 | 0.530 |
Why?
| | Quality of Health Care | 1 | 2020 | 578 | 0.530 |
Why?
| | Proton Pump Inhibitors | 5 | 2020 | 96 | 0.530 |
Why?
| | Mastocytosis | 2 | 2023 | 12 | 0.530 |
Why?
| | Breast Feeding | 6 | 2023 | 371 | 0.510 |
Why?
| | Monitoring, Physiologic | 1 | 2017 | 252 | 0.510 |
Why?
| | Psychometrics | 2 | 2022 | 617 | 0.510 |
Why?
| | Trust | 1 | 2016 | 108 | 0.510 |
Why?
| | Immunization | 4 | 2019 | 402 | 0.500 |
Why?
| | Patient Outcome Assessment | 1 | 2016 | 123 | 0.500 |
Why?
| | Angioedema | 1 | 2015 | 17 | 0.500 |
Why?
| | Health Status Indicators | 1 | 2015 | 155 | 0.490 |
Why?
| | Drug Labeling | 1 | 2014 | 42 | 0.480 |
Why?
| | Antigens, Plant | 4 | 2019 | 49 | 0.480 |
Why?
| | Young Adult | 13 | 2020 | 10518 | 0.470 |
Why?
| | United Kingdom | 5 | 2023 | 230 | 0.470 |
Why?
| | Anti-Inflammatory Agents | 1 | 2017 | 447 | 0.460 |
Why?
| | Ovalbumin | 2 | 2013 | 166 | 0.460 |
Why?
| | Referral and Consultation | 2 | 2015 | 647 | 0.460 |
Why?
| | Health Services Accessibility | 1 | 2020 | 771 | 0.450 |
Why?
| | Mass Screening | 2 | 2019 | 1023 | 0.450 |
Why?
| | Adrenal Cortex Hormones | 6 | 2023 | 510 | 0.450 |
Why?
| | Iron-Dextran Complex | 2 | 2023 | 10 | 0.440 |
Why?
| | Cross-Sectional Studies | 8 | 2023 | 4449 | 0.440 |
Why?
| | Comorbidity | 4 | 2021 | 1476 | 0.440 |
Why?
| | Decision Making | 4 | 2020 | 792 | 0.440 |
Why?
| | Retrospective Studies | 13 | 2022 | 12616 | 0.440 |
Why?
| | Excipients | 2 | 2023 | 49 | 0.430 |
Why?
| | Immunologic Tests | 3 | 2020 | 16 | 0.430 |
Why?
| | Polyethylene Glycols | 3 | 2023 | 576 | 0.430 |
Why?
| | Glucocorticoids | 4 | 2020 | 551 | 0.420 |
Why?
| | Lupus Erythematosus, Systemic | 1 | 2015 | 222 | 0.420 |
Why?
| | Animals | 21 | 2023 | 32123 | 0.410 |
Why?
| | Middle Aged | 15 | 2022 | 27084 | 0.400 |
Why?
| | Internet | 1 | 2016 | 596 | 0.400 |
Why?
| | Bacterial Proteins | 1 | 2017 | 739 | 0.400 |
Why?
| | Psychology, Educational | 1 | 2011 | 5 | 0.390 |
Why?
| | Feeding Behavior | 1 | 2017 | 573 | 0.390 |
Why?
| | Health Status Disparities | 1 | 2013 | 208 | 0.380 |
Why?
| | Insect Bites and Stings | 2 | 2023 | 12 | 0.370 |
Why?
| | Immunologic Deficiency Syndromes | 2 | 2022 | 75 | 0.370 |
Why?
| | Medical Overuse | 2 | 2021 | 31 | 0.370 |
Why?
| | Diet Therapy | 3 | 2017 | 36 | 0.370 |
Why?
| | Mental Health | 3 | 2021 | 573 | 0.370 |
Why?
| | Infant, Newborn | 9 | 2021 | 5089 | 0.360 |
Why?
| | Pregnancy Complications | 1 | 2015 | 431 | 0.360 |
Why?
| | Time Factors | 7 | 2020 | 6186 | 0.360 |
Why?
| | Treatment Outcome | 11 | 2024 | 9166 | 0.350 |
Why?
| | Cattle | 3 | 2023 | 935 | 0.350 |
Why?
| | Disease Management | 5 | 2021 | 562 | 0.340 |
Why?
| | Gastroenterology | 3 | 2020 | 158 | 0.340 |
Why?
| | Pigments, Biological | 1 | 2009 | 12 | 0.340 |
Why?
| | Sensitivity and Specificity | 3 | 2019 | 1728 | 0.340 |
Why?
| | RNA, Messenger | 3 | 2021 | 2581 | 0.340 |
Why?
| | Cohort Studies | 6 | 2022 | 4960 | 0.330 |
Why?
| | Weaning | 2 | 2020 | 48 | 0.320 |
Why?
| | Self Care | 3 | 2017 | 354 | 0.320 |
Why?
| | Azithromycin | 1 | 2009 | 80 | 0.310 |
Why?
| | Physician-Patient Relations | 3 | 2024 | 466 | 0.310 |
Why?
| | Double-Blind Method | 4 | 2023 | 1665 | 0.300 |
Why?
| | Administration, Cutaneous | 3 | 2023 | 116 | 0.300 |
Why?
| | Emergencies | 2 | 2019 | 150 | 0.300 |
Why?
| | Anxiety | 4 | 2021 | 853 | 0.300 |
Why?
| | Pregnancy | 6 | 2023 | 5556 | 0.290 |
Why?
| | Pediatricians | 2 | 2020 | 125 | 0.290 |
Why?
| | Health Status | 3 | 2021 | 733 | 0.290 |
Why?
| | Goals | 2 | 2018 | 159 | 0.290 |
Why?
| | Prospective Studies | 8 | 2022 | 6267 | 0.280 |
Why?
| | Severity of Illness Index | 6 | 2021 | 2598 | 0.270 |
Why?
| | Administration, Sublingual | 2 | 2018 | 13 | 0.270 |
Why?
| | Prevalence | 6 | 2022 | 2270 | 0.270 |
Why?
| | Patient Acceptance of Health Care | 3 | 2022 | 682 | 0.270 |
Why?
| | Administration, Topical | 3 | 2020 | 137 | 0.260 |
Why?
| | Egg Proteins | 2 | 2016 | 19 | 0.260 |
Why?
| | Chronic Disease | 3 | 2022 | 1602 | 0.260 |
Why?
| | Vaccines, Inactivated | 2 | 2018 | 67 | 0.260 |
Why?
| | Expert Testimony | 3 | 2020 | 55 | 0.260 |
Why?
| | Self Report | 2 | 2020 | 701 | 0.250 |
Why?
| | Periodicals as Topic | 2 | 2019 | 181 | 0.250 |
Why?
| | Risk Factors | 9 | 2022 | 8714 | 0.240 |
Why?
| | Bayes Theorem | 2 | 2022 | 336 | 0.230 |
Why?
| | Clinical Trials as Topic | 3 | 2024 | 945 | 0.230 |
Why?
| | Janus Kinase Inhibitors | 1 | 2023 | 10 | 0.230 |
Why?
| | Budesonide, Formoterol Fumarate Drug Combination | 1 | 2023 | 1 | 0.230 |
Why?
| | Histamine Antagonists | 2 | 2023 | 20 | 0.230 |
Why?
| | Infant Food | 2 | 2022 | 63 | 0.230 |
Why?
| | Australia | 3 | 2020 | 206 | 0.230 |
Why?
| | Food, Formulated | 2 | 2020 | 17 | 0.230 |
Why?
| | State Medicine | 1 | 2023 | 18 | 0.220 |
Why?
| | Insecta | 2 | 2017 | 63 | 0.220 |
Why?
| | Chicago | 2 | 2022 | 45 | 0.220 |
Why?
| | Diagnosis, Differential | 4 | 2021 | 1359 | 0.220 |
Why?
| | Immunologic Factors | 2 | 2022 | 219 | 0.220 |
Why?
| | Dermatologic Agents | 1 | 2023 | 57 | 0.220 |
Why?
| | Patient Safety | 2 | 2018 | 276 | 0.220 |
Why?
| | Dilatation | 2 | 2020 | 59 | 0.220 |
Why?
| | Emollients | 1 | 2022 | 11 | 0.210 |
Why?
| | Books | 1 | 2022 | 3 | 0.210 |
Why?
| | Injections | 2 | 2021 | 163 | 0.210 |
Why?
| | Immunity | 1 | 2023 | 124 | 0.210 |
Why?
| | Guideline Adherence | 2 | 2019 | 494 | 0.210 |
Why?
| | Nasal Polyps | 1 | 2022 | 49 | 0.210 |
Why?
| | Reproducibility of Results | 3 | 2022 | 2814 | 0.200 |
Why?
| | Societies, Medical | 3 | 2020 | 690 | 0.200 |
Why?
| | Prognosis | 3 | 2020 | 3342 | 0.200 |
Why?
| | Lactation | 1 | 2023 | 149 | 0.200 |
Why?
| | Genetic Diseases, X-Linked | 1 | 2022 | 23 | 0.200 |
Why?
| | Follow-Up Studies | 4 | 2022 | 4446 | 0.200 |
Why?
| | Asparaginase | 1 | 2021 | 29 | 0.200 |
Why?
| | Agammaglobulinemia | 1 | 2022 | 31 | 0.200 |
Why?
| | Parents | 3 | 2023 | 1210 | 0.200 |
Why?
| | Vaccines, Synthetic | 1 | 2022 | 123 | 0.200 |
Why?
| | Emergency Service, Hospital | 3 | 2023 | 1842 | 0.190 |
Why?
| | Patient Education as Topic | 2 | 2020 | 686 | 0.190 |
Why?
| | Algorithms | 3 | 2021 | 1494 | 0.190 |
Why?
| | Symptom Assessment | 2 | 2020 | 121 | 0.190 |
Why?
| | Child Day Care Centers | 1 | 2021 | 33 | 0.190 |
Why?
| | Family | 3 | 2021 | 591 | 0.190 |
Why?
| | Drug Prescriptions | 1 | 2023 | 241 | 0.190 |
Why?
| | Immunoglobulins, Intravenous | 1 | 2022 | 123 | 0.190 |
Why?
| | Esophagoscopy | 2 | 2020 | 183 | 0.190 |
Why?
| | Pilot Projects | 2 | 2018 | 1374 | 0.190 |
Why?
| | Breath Tests | 2 | 2018 | 85 | 0.180 |
Why?
| | Randomized Controlled Trials as Topic | 6 | 2023 | 1216 | 0.180 |
Why?
| | Sleep Initiation and Maintenance Disorders | 1 | 2022 | 116 | 0.180 |
Why?
| | Adrenergic alpha-Agonists | 1 | 2020 | 29 | 0.180 |
Why?
| | Terbutaline | 1 | 2020 | 8 | 0.180 |
Why?
| | Educational Personnel | 1 | 2020 | 13 | 0.180 |
Why?
| | Hoarding | 1 | 2020 | 2 | 0.180 |
Why?
| | Probability | 2 | 2022 | 297 | 0.180 |
Why?
| | Sinusitis | 1 | 2022 | 175 | 0.180 |
Why?
| | Military Medicine | 1 | 2022 | 93 | 0.180 |
Why?
| | North America | 1 | 2021 | 262 | 0.180 |
Why?
| | Consensus Development Conferences as Topic | 1 | 2020 | 29 | 0.180 |
Why?
| | Antibody Specificity | 2 | 2017 | 180 | 0.180 |
Why?
| | beta-Lactams | 1 | 2020 | 27 | 0.180 |
Why?
| | Mass Media | 1 | 2020 | 38 | 0.180 |
Why?
| | Plant Bark | 1 | 2019 | 11 | 0.170 |
Why?
| | Drug Approval | 1 | 2020 | 78 | 0.170 |
Why?
| | Albuterol | 1 | 2020 | 106 | 0.170 |
Why?
| | Access to Information | 1 | 2020 | 50 | 0.170 |
Why?
| | Insurance Claim Review | 1 | 2020 | 67 | 0.170 |
Why?
| | Equipment Failure | 1 | 2020 | 109 | 0.170 |
Why?
| | Precision Medicine | 2 | 2020 | 356 | 0.170 |
Why?
| | Syndrome | 2 | 2017 | 339 | 0.170 |
Why?
| | Europe | 2 | 2018 | 352 | 0.170 |
Why?
| | Anti-Infective Agents | 1 | 2022 | 225 | 0.170 |
Why?
| | Social Determinants of Health | 1 | 2021 | 138 | 0.170 |
Why?
| | Public Facilities | 1 | 2019 | 4 | 0.170 |
Why?
| | Network Meta-Analysis | 3 | 2023 | 17 | 0.170 |
Why?
| | Monte Carlo Method | 1 | 2019 | 140 | 0.170 |
Why?
| | Transdermal Patch | 1 | 2019 | 15 | 0.170 |
Why?
| | Aged, 80 and over | 3 | 2020 | 6438 | 0.170 |
Why?
| | Pollen | 1 | 2019 | 25 | 0.170 |
Why?
| | False Negative Reactions | 1 | 2019 | 52 | 0.170 |
Why?
| | Crying | 1 | 2019 | 14 | 0.160 |
Why?
| | Infant Behavior | 1 | 2019 | 23 | 0.160 |
Why?
| | False Positive Reactions | 1 | 2019 | 111 | 0.160 |
Why?
| | Benchmarking | 1 | 2020 | 165 | 0.160 |
Why?
| | Income | 2 | 2023 | 170 | 0.160 |
Why?
| | Equipment Design | 1 | 2020 | 516 | 0.160 |
Why?
| | Drugs, Generic | 1 | 2018 | 18 | 0.160 |
Why?
| | Models, Economic | 1 | 2019 | 48 | 0.160 |
Why?
| | Cost Savings | 1 | 2019 | 74 | 0.160 |
Why?
| | Needles | 1 | 2019 | 52 | 0.160 |
Why?
| | Reference Standards | 1 | 2019 | 161 | 0.160 |
Why?
| | Public Health Surveillance | 1 | 2018 | 61 | 0.160 |
Why?
| | Health Planning Guidelines | 1 | 2018 | 25 | 0.160 |
Why?
| | Models, Econometric | 1 | 2018 | 34 | 0.160 |
Why?
| | Virtual Reality | 1 | 2019 | 37 | 0.160 |
Why?
| | Gastrointestinal Microbiome | 2 | 2022 | 503 | 0.160 |
Why?
| | New Zealand | 1 | 2018 | 49 | 0.160 |
Why?
| | Vomiting | 1 | 2019 | 125 | 0.160 |
Why?
| | Patient Preference | 1 | 2020 | 171 | 0.160 |
Why?
| | Pruritus | 3 | 2023 | 61 | 0.160 |
Why?
| | Biopsy | 3 | 2019 | 1056 | 0.150 |
Why?
| | Respiratory Sounds | 1 | 2019 | 114 | 0.150 |
Why?
| | Exanthema | 1 | 2019 | 77 | 0.150 |
Why?
| | Heparin | 1 | 2019 | 226 | 0.150 |
Why?
| | Cough | 1 | 2019 | 109 | 0.150 |
Why?
| | Work Performance | 1 | 2018 | 6 | 0.150 |
Why?
| | Hydrolysis | 1 | 2018 | 179 | 0.150 |
Why?
| | Travel | 1 | 2019 | 121 | 0.150 |
Why?
| | Eating | 2 | 2019 | 350 | 0.150 |
Why?
| | RNA, Viral | 1 | 2021 | 561 | 0.150 |
Why?
| | Early Medical Intervention | 1 | 2018 | 51 | 0.150 |
Why?
| | Information Dissemination | 1 | 2020 | 192 | 0.150 |
Why?
| | Immune Sera | 1 | 2017 | 80 | 0.150 |
Why?
| | Administration, Intravenous | 1 | 2018 | 126 | 0.150 |
Why?
| | Aged | 5 | 2022 | 19299 | 0.150 |
Why?
| | Nasal Obstruction | 1 | 2017 | 22 | 0.150 |
Why?
| | Mothers | 1 | 2023 | 667 | 0.140 |
Why?
| | Dietary Fats | 1 | 2019 | 291 | 0.140 |
Why?
| | Uncertainty | 1 | 2017 | 98 | 0.140 |
Why?
| | Prenatal Exposure Delayed Effects | 1 | 2022 | 449 | 0.140 |
Why?
| | Venoms | 1 | 2017 | 30 | 0.140 |
Why?
| | Asthma, Exercise-Induced | 1 | 2016 | 6 | 0.140 |
Why?
| | Transgenes | 1 | 2017 | 169 | 0.140 |
Why?
| | Bronchoconstriction | 1 | 2016 | 27 | 0.140 |
Why?
| | Hematopoietic Stem Cell Transplantation | 1 | 2022 | 524 | 0.140 |
Why?
| | Linear Models | 2 | 2020 | 778 | 0.140 |
Why?
| | Behavior | 1 | 2017 | 91 | 0.140 |
Why?
| | Fatty Acids | 1 | 2019 | 385 | 0.140 |
Why?
| | Child Nutritional Physiological Phenomena | 1 | 2017 | 97 | 0.130 |
Why?
| | Environmental Pollutants | 1 | 2018 | 112 | 0.130 |
Why?
| | Phenotype | 3 | 2020 | 2861 | 0.130 |
Why?
| | Drug Administration Schedule | 1 | 2018 | 724 | 0.130 |
Why?
| | Observer Variation | 1 | 2016 | 299 | 0.130 |
Why?
| | Health Surveys | 2 | 2020 | 449 | 0.130 |
Why?
| | Hospitals, Special | 1 | 2015 | 10 | 0.130 |
Why?
| | Tertiary Healthcare | 1 | 2015 | 29 | 0.130 |
Why?
| | Secondary Prevention | 1 | 2017 | 223 | 0.130 |
Why?
| | Protein-Losing Enteropathies | 1 | 2015 | 11 | 0.130 |
Why?
| | Costs and Cost Analysis | 1 | 2016 | 200 | 0.130 |
Why?
| | Computer Simulation | 1 | 2019 | 887 | 0.130 |
Why?
| | Lymphopenia | 1 | 2015 | 49 | 0.130 |
Why?
| | Patient Selection | 1 | 2019 | 656 | 0.130 |
Why?
| | Hospitalization | 2 | 2021 | 1761 | 0.120 |
Why?
| | Michigan | 1 | 2014 | 95 | 0.120 |
Why?
| | Self Efficacy | 1 | 2018 | 361 | 0.120 |
Why?
| | Academic Medical Centers | 1 | 2017 | 415 | 0.120 |
Why?
| | Hypertension | 1 | 2022 | 1063 | 0.120 |
Why?
| | Inhalation | 1 | 2014 | 25 | 0.120 |
Why?
| | Population Surveillance | 1 | 2017 | 396 | 0.120 |
Why?
| | Injections, Subcutaneous | 1 | 2014 | 137 | 0.110 |
Why?
| | Dose-Response Relationship, Immunologic | 1 | 2013 | 82 | 0.110 |
Why?
| | Epigenesis, Genetic | 1 | 2018 | 531 | 0.110 |
Why?
| | Skin | 1 | 2018 | 668 | 0.110 |
Why?
| | Perioperative Period | 1 | 2013 | 49 | 0.110 |
Why?
| | Government Regulation | 1 | 2013 | 46 | 0.110 |
Why?
| | Fontan Procedure | 1 | 2015 | 157 | 0.110 |
Why?
| | Medication Adherence | 1 | 2017 | 536 | 0.110 |
Why?
| | Prebiotics | 2 | 2023 | 23 | 0.100 |
Why?
| | Cardiovascular Diseases | 1 | 2024 | 1724 | 0.100 |
Why?
| | Administration, Inhalation | 2 | 2023 | 647 | 0.100 |
Why?
| | Biomarkers | 2 | 2020 | 3474 | 0.100 |
Why?
| | Disease Progression | 2 | 2020 | 2424 | 0.090 |
Why?
| | Triticum | 1 | 2010 | 10 | 0.090 |
Why?
| | Pyroglyphidae | 2 | 2022 | 17 | 0.090 |
Why?
| | Clinical Competence | 1 | 2017 | 918 | 0.090 |
Why?
| | Immunization, Secondary | 1 | 2010 | 82 | 0.090 |
Why?
| | Residence Characteristics | 1 | 2012 | 277 | 0.090 |
Why?
| | CD8-Positive T-Lymphocytes | 1 | 2015 | 686 | 0.090 |
Why?
| | Lung | 2 | 2024 | 3685 | 0.090 |
Why?
| | Adrenergic Agonists | 1 | 2009 | 5 | 0.090 |
Why?
| | Aviation | 1 | 2009 | 9 | 0.090 |
Why?
| | Food Coloring Agents | 1 | 2009 | 1 | 0.090 |
Why?
| | Hemiptera | 1 | 2009 | 1 | 0.090 |
Why?
| | Histamine H1 Antagonists | 1 | 2009 | 33 | 0.090 |
Why?
| | Comprehension | 1 | 2011 | 159 | 0.090 |
Why?
| | Empathy | 1 | 2011 | 141 | 0.080 |
Why?
| | Physician's Role | 1 | 2011 | 198 | 0.080 |
Why?
| | CD4-Positive T-Lymphocytes | 1 | 2015 | 965 | 0.080 |
Why?
| | Tablets | 1 | 2009 | 36 | 0.080 |
Why?
| | Dose-Response Relationship, Drug | 1 | 2013 | 1868 | 0.080 |
Why?
| | Coloring Agents | 1 | 2009 | 71 | 0.080 |
Why?
| | Cardiac Surgical Procedures | 1 | 2013 | 433 | 0.080 |
Why?
| | Sex Factors | 1 | 2014 | 1741 | 0.080 |
Why?
| | Heart Defects, Congenital | 1 | 2015 | 682 | 0.080 |
Why?
| | Primary Health Care | 2 | 2021 | 1517 | 0.080 |
Why?
| | Stress, Psychological | 1 | 2016 | 975 | 0.080 |
Why?
| | Arthropod Venoms | 1 | 2007 | 2 | 0.080 |
Why?
| | Tryptases | 1 | 2007 | 10 | 0.080 |
Why?
| | Occupational Diseases | 1 | 2009 | 129 | 0.080 |
Why?
| | Disease Susceptibility | 2 | 2020 | 321 | 0.070 |
Why?
| | Vitamin D | 2 | 2022 | 341 | 0.070 |
Why?
| | Data Collection | 1 | 2009 | 636 | 0.070 |
Why?
| | Risk-Taking | 1 | 2009 | 333 | 0.070 |
Why?
| | Predictive Value of Tests | 1 | 2010 | 1817 | 0.060 |
Why?
| | Adaptation, Psychological | 2 | 2020 | 551 | 0.060 |
Why?
| | Formoterol Fumarate | 1 | 2023 | 8 | 0.060 |
Why?
| | Ethanolamines | 1 | 2023 | 20 | 0.060 |
Why?
| | Budesonide | 1 | 2023 | 87 | 0.060 |
Why?
| | Beneficence | 1 | 2023 | 18 | 0.050 |
Why?
| | Dermatophagoides pteronyssinus | 1 | 2022 | 5 | 0.050 |
Why?
| | Drug Combinations | 1 | 2023 | 288 | 0.050 |
Why?
| | Moscow | 1 | 2022 | 1 | 0.050 |
Why?
| | Sample Size | 1 | 2023 | 119 | 0.050 |
Why?
| | Administration, Intranasal | 1 | 2022 | 76 | 0.050 |
Why?
| | Electronic Health Records | 2 | 2021 | 801 | 0.050 |
Why?
| | Tacrolimus | 1 | 2023 | 143 | 0.050 |
Why?
| | Ukraine | 1 | 2022 | 10 | 0.050 |
Why?
| | Baths | 1 | 2022 | 17 | 0.050 |
Why?
| | Dietary Fiber | 1 | 2022 | 40 | 0.050 |
Why?
| | Geography | 1 | 2022 | 185 | 0.050 |
Why?
| | Multicenter Studies as Topic | 1 | 2022 | 249 | 0.050 |
Why?
| | Child, Hospitalized | 1 | 2022 | 39 | 0.050 |
Why?
| | Forecasting | 1 | 2023 | 332 | 0.050 |
Why?
| | History, 20th Century | 1 | 2022 | 276 | 0.050 |
Why?
| | Russia | 1 | 2020 | 9 | 0.050 |
Why?
| | Patient Care Management | 1 | 2021 | 55 | 0.050 |
Why?
| | Milk, Human | 1 | 2022 | 128 | 0.050 |
Why?
| | London | 1 | 2020 | 42 | 0.050 |
Why?
| | Professionalism | 1 | 2020 | 14 | 0.040 |
Why?
| | Guilt | 1 | 2020 | 11 | 0.040 |
Why?
| | Patient Care Planning | 1 | 2021 | 142 | 0.040 |
Why?
| | Grief | 1 | 2020 | 35 | 0.040 |
Why?
| | Health Care Rationing | 1 | 2020 | 47 | 0.040 |
Why?
| | Risk Management | 1 | 2021 | 89 | 0.040 |
Why?
| | Aspirin | 1 | 2022 | 326 | 0.040 |
Why?
| | Publication Bias | 1 | 2020 | 38 | 0.040 |
Why?
| | Biological Variation, Individual | 1 | 2019 | 2 | 0.040 |
Why?
| | No-Observed-Adverse-Effect Level | 1 | 2019 | 5 | 0.040 |
Why?
| | Cytokines | 1 | 2007 | 1857 | 0.040 |
Why?
| | Immunosuppressive Agents | 1 | 2023 | 666 | 0.040 |
Why?
| | Efficiency | 1 | 2020 | 85 | 0.040 |
Why?
| | Documentation | 1 | 2021 | 169 | 0.040 |
Why?
| | Placebo Effect | 1 | 2019 | 51 | 0.040 |
Why?
| | Maximum Tolerated Dose | 1 | 2019 | 182 | 0.040 |
Why?
| | Spirituality | 1 | 2020 | 69 | 0.040 |
Why?
| | Interdisciplinary Communication | 1 | 2020 | 185 | 0.040 |
Why?
| | Medical History Taking | 1 | 2019 | 115 | 0.040 |
Why?
| | Staphylococcus aureus | 1 | 2022 | 386 | 0.040 |
Why?
| | Hematologic Tests | 1 | 2018 | 22 | 0.040 |
Why?
| | Drug Delivery Systems | 1 | 2021 | 301 | 0.040 |
Why?
| | Confidence Intervals | 1 | 2019 | 310 | 0.040 |
Why?
| | Th1-Th2 Balance | 1 | 2018 | 10 | 0.040 |
Why?
| | Mindfulness | 1 | 2020 | 99 | 0.040 |
Why?
| | Poverty | 1 | 2021 | 444 | 0.040 |
Why?
| | Hygiene | 1 | 2018 | 28 | 0.040 |
Why?
| | Hospitals | 1 | 2022 | 581 | 0.040 |
Why?
| | Endoscopy, Digestive System | 1 | 2019 | 109 | 0.040 |
Why?
| | Skin Irritancy Tests | 1 | 2017 | 3 | 0.040 |
Why?
| | Social Behavior | 1 | 2020 | 267 | 0.040 |
Why?
| | Combined Modality Therapy | 1 | 2020 | 1128 | 0.040 |
Why?
| | Dietetics | 1 | 2017 | 22 | 0.040 |
Why?
| | Health Care Surveys | 1 | 2019 | 540 | 0.040 |
Why?
| | Societies, Scientific | 1 | 2017 | 46 | 0.040 |
Why?
| | Nutritional Sciences | 1 | 2017 | 35 | 0.040 |
Why?
| | Research | 1 | 2020 | 398 | 0.040 |
Why?
| | Protective Factors | 1 | 2017 | 87 | 0.040 |
Why?
| | Bias | 1 | 2017 | 184 | 0.030 |
Why?
| | Child Abuse | 1 | 2021 | 455 | 0.030 |
Why?
| | Ambulatory Care | 1 | 2020 | 480 | 0.030 |
Why?
| | Patient Discharge | 1 | 2022 | 770 | 0.030 |
Why?
| | Gene-Environment Interaction | 1 | 2018 | 194 | 0.030 |
Why?
| | Lipid Metabolism | 1 | 2019 | 449 | 0.030 |
Why?
| | Immunoglobulin Isotypes | 1 | 2015 | 32 | 0.030 |
Why?
| | Perception | 1 | 2018 | 316 | 0.030 |
Why?
| | Quality Assurance, Health Care | 1 | 2017 | 319 | 0.030 |
Why?
| | Eye Diseases | 1 | 2016 | 76 | 0.030 |
Why?
| | CD4 Lymphocyte Count | 1 | 2015 | 257 | 0.030 |
Why?
| | Odds Ratio | 1 | 2017 | 969 | 0.030 |
Why?
| | Respiratory Tract Diseases | 1 | 2016 | 142 | 0.030 |
Why?
| | Antibodies, Monoclonal | 1 | 2020 | 1262 | 0.030 |
Why?
| | Suicide | 1 | 2020 | 501 | 0.030 |
Why?
| | Anesthesia, General | 1 | 2013 | 44 | 0.030 |
Why?
| | Emotions | 1 | 2018 | 486 | 0.030 |
Why?
| | Anesthetics | 1 | 2013 | 57 | 0.030 |
Why?
| | Quality Improvement | 1 | 2020 | 956 | 0.030 |
Why?
| | Immunity, Innate | 1 | 2018 | 734 | 0.030 |
Why?
| | Stress Disorders, Post-Traumatic | 1 | 2020 | 751 | 0.030 |
Why?
| | Substance-Related Disorders | 1 | 2020 | 953 | 0.020 |
Why?
| | Depression | 1 | 2020 | 1149 | 0.020 |
Why?
| | Anesthesia | 1 | 2013 | 119 | 0.020 |
Why?
| | Diarrhea | 1 | 2012 | 173 | 0.020 |
Why?
| | Abdominal Pain | 1 | 2012 | 137 | 0.020 |
Why?
| | Genetic Predisposition to Disease | 1 | 2019 | 2209 | 0.020 |
Why?
| | Recurrence | 1 | 2013 | 949 | 0.020 |
Why?
| | Disease Models, Animal | 1 | 2019 | 3582 | 0.020 |
Why?
| | Case-Control Studies | 1 | 2015 | 3054 | 0.020 |
Why?
| | Signal Transduction | 1 | 2019 | 4526 | 0.020 |
Why?
|
|
Greenhawt's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|